Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPEbeGONE_DS
NCT06042257Phase 2Terminated
- Start
- Dec 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) and impulse control disorder (ICD) comparing Guanfacine Hydrochloride Immediate Release with Placebo (2 arms). Primary endpoint: Aberrant Behavior Checklist-Hyperactivity subscale score at 8 weeks. Started Dec 2024; status: terminated.
02
Drugs
guanfacine
03
Conditions
attention deficit hyperactivity disorder (ADHD)impulse control disorder (ICD)
Beyond the preview
Go deeper on NCT06042257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06042257.